Corient Private Wealth’s TRACON Pharmaceuticals TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-2,873
Closed -$24.7K – 2409
2024
Q1
$24.7K Hold
2,873
– – ﹤0.01% 2255
2023
Q4
$10.1K Hold
2,873
– – ﹤0.01% 2238
2023
Q3
$10.2K Hold
2,873
– – ﹤0.01% 2122
2023
Q2
$16.7K Hold
2,873
– – ﹤0.01% 2056
2023
Q1
$109K Hold
2,873
– – ﹤0.01% 1872
2022
Q4
$85.6K Buy
+2,873
New +$86.9K ﹤0.01% 1585

Other funds holding TCON

Corient Private Wealth's TCON Position: Q2 2024 in Review

Corient Private Wealth sold out of TRACON Pharmaceuticals (TCON) in Q2 2024, closing a stake of 2,873 shares — an estimated $24.7K sold.

Corient Private Wealth first reported a position in TCON in Q4 2022 and held it in 6 quarters. The position peaked at $109K in Q1 2023. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.

  • Corient Private Wealth reported no remaining TRACON Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Corient Private Wealth sold 2,873 TRACON Pharmaceuticals shares in Q2 2024, an estimated $24.7K.
  • Corient Private Wealth first reported a position in TRACON Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Corient Private Wealth's TRACON Pharmaceuticals position peaked at $109K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals as of Q2 2024.

Based on Corient Private Wealth's 13F filing for Q2 2024, filed 13 Aug 2024.